Pharmacokinetics and Excretion of 14C-Bendamustine in Patients with Relapsed or Refractory Malignancy

201339 citationsJournal Articlegold Open Access

Authors

Anne-Charlotte Dubbelman · The Netherlands Cancer Institute

Hilde Rosing · The Netherlands Cancer Institute

Mona Darwish · Teva Pharmaceuticals (United States)

Denise D’Andrea · Teva Pharmaceuticals (United States)

Mary Lou Bond · Teva Pharmaceuticals (United States)

Edward T. Hellriegel

Philmore Robertson

Jos H. Beijnen

Abstract

Bendamustine is extensively metabolized, with subsequent excretion in both urine and feces. Accumulation of bendamustine is not anticipated in cancer patients with renal or hepatic impairment, because of the dose administration schedule and short half-life.

Topics & Keywords

Cancer Treatment and Pharmacology Chronic Lymphocytic Leukemia Research Colorectal Cancer Treatments and Studies

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Drugs in R&D

Volume 13, Issue 1, pp. 17-28

DOI: 10.1007/s40268-012-0001-5

Field-Weighted Citation Impact: 2.67